Coldstream Capital Management Inc. boosted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 14.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,212 shares of the biopharmaceutical company’s stock after acquiring an additional 13,535 shares during the period. Coldstream Capital Management Inc.’s holdings in Pfizer were worth $3,114,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gladius Capital Management LP lifted its position in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. MFA Wealth Advisors LLC purchased a new stake in Pfizer in the second quarter valued at $29,000. Quarry LP purchased a new stake in Pfizer in the second quarter valued at $31,000. Financial Connections Group Inc. purchased a new stake in Pfizer in the second quarter valued at $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the third quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Pfizer
In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Stock Report on Pfizer
Pfizer Stock Down 2.0 %
PFE stock opened at $25.58 on Wednesday. The company has a market cap of $144.96 billion, a P/E ratio of 34.57, a P/E/G ratio of 0.71 and a beta of 0.65. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company’s 50-day moving average price is $27.42 and its 200 day moving average price is $28.36. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, research analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 8th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.57%. The ex-dividend date was Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
- Five stocks we like better than Pfizer
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- Investing in Commodities: What Are They? How to Invest in Them
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- How to Calculate Options Profits
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.